Key facts
- AMPLY Discovery’s last known valuation is $7.5M (May 2025).
- It has raised $3.4M; the latest was Later Stage VC ($2.3M) in Jan 2026.
- Notable investors include Techstars, Innovate UK, EIT Food, British Business Bank, Clarendon Fund Managers — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for AMPLY Discovery
- ·The full record, as it builds
Funding rounds
No funding rounds for AMPLY Discovery are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AMPLY Discovery
Developer of a drug discovery studio designed to discover new cures for cancer, metabolic disease, and infectious diseases through artificial intelligence (AI) and synthetic biology. The company uses machine learning and synthetic biology, which digitizes life's natural diversity and identifies putative drug candidates based on function, enabling research entities to find new therapeutic molecules for hard-to-treat diseases.
- Sector
- Healthcare
- HQ
- Belfast, United Kingdom
- Founded
- 2021
- Employees
- 6
- Website
- amplydiscovery.com/
- Ownership
- Privately Held (backing)
AMPLY Discovery doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AMPLY Discovery shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AMPLY Discovery in its N-PORT filings yet. We sweep new filings monthly.